Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
December 07, 2023 15:34 ET
|
ResMed Inc.
New study shows Chronic Obstructive Pulmonary Disease (COPD) increasing globally through 2050, with 47% growth among women.
ResMed Adopts New Operating Model to Accelerate Long-term Growth
November 09, 2023 16:05 ET
|
ResMed Inc.
Justin Leong appointed Chief Product Officer, effective immediately.Katrin Pucknat appointed Chief Marketing Officer, effective immediately.Mike Fliss appointed Chief Revenue Officer, effective...
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
October 26, 2023 16:05 ET
|
ResMed Inc.
Year-over-year revenue grows 16%, operating profit up 5%, non-GAAP operating profit up 10%Expects to resume its share repurchase program during upcoming quarter Note: A webcast of ResMed’s conference...
ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023
October 05, 2023 16:05 ET
|
ResMed Inc.
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2024 on Thursday,...
ResMed Announces Participation in Upcoming Conferences
September 05, 2023 16:05 ET
|
ResMed Inc.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced its participation in two upcoming conferences. Mick Farrell, chief executive officer and chair of the...
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2023
August 03, 2023 16:05 ET
|
ResMed Inc.
Year-over-year revenue grows 23%, operating profit up 8%, non-GAAP operating profit up 13%Quarterly dividend increases 9% to $0.48 per share Note: A webcast of ResMed’s conference call will be...
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023
July 06, 2023 16:05 ET
|
ResMed Inc.
SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2023 on...
ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software
July 05, 2023 16:05 ET
|
ResMed Inc.
Expands ResMed’s sleep management software solution, will help sleep labs and physicians more efficiently guide patients into and through diagnosis to long-term treatmentDiagnostic management platform...
PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP
June 08, 2023 09:00 ET
|
ResMed Inc.
The studies also showed 18-40% lower costs incurred from ER visits and hospitalizations after 1 year for PAP-adherent OSA patients with diastolic and systolic heart failure, respectivelyA third study...
ResMed Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023 16:05 ET
|
ResMed Inc.
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the Goldman Sachs...